10,000 Shares in Illumina, Inc. $ILMN Bought by K.J. Harrison & Partners Inc

K.J. Harrison & Partners Inc bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 1st quarter, Holdings Channel reports. The institutional investor bought 10,000 shares of the life sciences company’s stock, valued at approximately $1,233,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB boosted its holdings in Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares in the last quarter. HighPoint Advisor Group LLC increased its holdings in shares of Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after acquiring an additional 80 shares in the last quarter. Toronto Dominion Bank increased its holdings in shares of Illumina by 0.3% during the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after acquiring an additional 92 shares in the last quarter. Panagora Asset Management Inc. increased its holdings in shares of Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after acquiring an additional 96 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its position in shares of Illumina by 4.2% in the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock valued at $323,000 after purchasing an additional 99 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Illumina

In related news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the sale, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. The trade was a 2.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,003,769 shares of company stock worth $155,710,908 in the last three months. 2.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ILMN shares. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Sanford C. Bernstein initiated coverage on shares of Illumina in a research note on Friday, June 26th. They set a “market perform” rating and a $185.00 price target on the stock. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Finally, Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $148.94.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $188.68 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm’s 50 day simple moving average is $154.74 and its 200-day simple moving average is $139.42. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $189.46. The stock has a market capitalization of $28.55 billion, a price-to-earnings ratio of 34.31, a PEG ratio of 3.53 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business earned $0.97 earnings per share. The firm’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts expect that Illumina, Inc. will post 5.21 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.